Q4 2024 Guidance -- Expected revenue between $71 million and $72 million; expected non-GAAP operating expenses of $50.5 million to $51.5 million; expected non-GAAP EPS of $0.23 to $0.24.
Zacks Small Cap Research on MSN
FBLG: Phase 1/2 trial in diabetic foot ulcers to initiate in 1Q26
FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Approval from HREC for Phase 1/2 Diabetic Foot Ulcer Trial In ...
Farm succession requires gradual transition through employee phase, targeted leadership exposure, active handoff and wise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback